Effects of Na+ channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 3, 2003, Pages 410-418

  Wu, Long Mei ^a   Orikabe, Minako ^a   Hirano, Yuji ^a   Kawano, Seiko ^a   Hiraoka, Masayasu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Activation of the HERG channel; Ikr; Open channel block; QT prolongation; Repolarization of action potential

Indexed keywords

PILSICAINIDE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ARTICLE; BINDING SITE; DRUG EFFECT; ETHER A GO GO RELATED GENE; GENE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HUMAN CELL; LONG QT SYNDROME; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; RECEPTOR AFFINITY;

ACTION POTENTIALS; CATION TRANSPORT PROTEINS; CELLS, CULTURED; DNA-BINDING PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIDOCAINE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; SODIUM CHANNEL BLOCKERS; TRANS-ACTIVATORS;

EID: 0041837590     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200309000-00013     Document Type: Article

References (32)

1. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270-283.
2. + channel diversity in the mammalian myocardium. J Physiol. 2000;525:285-298.
3. Trudeau MC, Warmke JW, Ganetzky B, et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995; 269:92-95.
4. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell. 1995;81:299-307.
5. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80: 805-811.
6. + current: differential sensitivity to block by class-III antiarrhythmic agents. J Gen Physiol. 1990;96:967-969.
7. Follmer CH, Cullinan CA, Colatsky TJ. Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res. 1992;26:1121-1130.
8. + current by almokalant in rabbit ventricular myocytes. Circ Res. 1993;73:857-868.
9. + current in rabbit ventricular myocytes. Cardiovasc Drug Ther. 1993;3:599-604.
10. kr) in AT-1 cells: Concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995;91:1799-1806.
11. Snyders DJ, Chaundhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol. 1996;49: 949-955.
12. + channel. Open-channel block by methanesulfonalides. Circ Res. 1996;78:499-503.
13. + channel: role of S6 in antiarrhythmic drug binding. Circ Res. 1996;78:1105-1114.
14. Yang T, Snyders DJ, Roden DM. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: Comparison with quinidine and dofetilide. J Pharmacol Exp Ther. 1997;280:1170-1175.
15. Busch AE, Eigenberger B, Jurkiewicz NK, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol. 1998;123:23-30.
16. Drolet B, Khaliha M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998;97: 204-210.
17. Zhang S. Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res. 1999;84:989-998.
18. Inomata N, Ishihara T, Akaike N. SUN 1165: A new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig. Com Biochem Physiol. 1987;87:237-243.
19. Hattori Y, Hidaka T, Aisaka K, et al. Effects of SUN 1165, a new antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol. 1988;11:407-412.
20. Yamashita T, Murakawa Y, Sezaki K, et al. Uniqueness of pilsicainide in class Ic antiarrhythmics. Jpn Heart J. 1998;39:389-397.
21. Kodama I, Ogawa S, Inoue H, et al. Profile of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. Jpn Circ J. 1999;63:1-12.
22. Hashimoto K, Ishii M, Komori S, et al. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide and SUN 1165. Heart Vessels. 1985;1:29-35.
23. Atarashi H, Inoue H, Hiejima K, et al. for the PSTAF Investigators. Conversion of recent onset atrial fibrillation by a single oral dose of pilsicainide. Am J Cardiol. 1996;78:694-697.
24. Okishige K, Nishizaki M, Azegami N, et al. and the Kanagawa Arrhythmia Task Force Investigators. Pilsicainide for conversion in chronic atrial fibrillation: A placebo-controlled, multicenter study. Am Heart J. 2000; 140:e13-e20.
25. Tohyou Y, Itoh A, Okabayashi K, et al. Effects of antiarrhythmic agent on electrocardiogram in patients with hemodyalisis (in Japanese). Therap Res. 1996;17:249-256.
26. Mitamura H, Saikawa T, Sugi K, et al. Ventricular proarrhythmic actions by anisrrhythmic drugs: Multicenter study (in Japanese). Cardiology. 1998;44:395-408.
27. Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230-241.
28. Nakajima T, Furukawa T, Tanaka T, et al. Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation. Circ Res. 1998;83:415-422.
29. + channels by vesnarinone. Mol Pharmacol. 2001;60:244-253.
30. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Pro Natl Acad Sci USA. 2000;97:12329-12333.
31. Yokota M, Miyahara T, Enomoto N, et al. Pharmacokinetics and pharmacodynamics of antiarrhythmic agent, SUN1165 (in Japanese). Therap Res. 1989;10:483-495.
32. Shiga T, Hashiguchi M, Urae A, et al. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67: 222-228.